NCT01447069

Use of Beta-agonists in Stable Severe Congestive Heart Failure

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Rabin Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether Salbutamol is effective in the treatment of severe heart failure due to ischemic and non- ischemic cardiomyopathy.

Conditions

• Ischemic Cardiomyopathy
• Non-ischemic Cardiomyopathy
• Heart Failure

Interventions

Type	Name	Description
DRUG	Salbutamol	The initial dose will be 0.5mg bid, with acceleration of the dose every two weeks by 1mg, up to a maximal dose of 2mg bid or an increase in heart rate by 50% above the baseline heart rate, as long as it remains \<100 bpm

Timeline

• Start date: 2011-10-01
• Primary completion: 2012-03-01
• Completion: 2012-03-01
• First posted: 2011-10-05
• Last updated: 2011-10-05

Locations

1 site across 1 country: Israel